Screener
Celldex Therapeutics CLDX Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's enterprise value?
- Celldex Therapeutics (CLDX) reported enterprise value of $2.88B in Q2 2026.
- How has Celldex Therapeutics's enterprise value changed year-over-year?
- Celldex Therapeutics's enterprise value increased by 103.1% year-over-year, from $1.42B to $2.88B.
- What is the long-term trend for Celldex Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), Celldex Therapeutics's enterprise value has grown at a 18.0% compound annual growth rate (CAGR), from $777.2M to $1.78B.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about Celldex Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude